ReviewClinical reviews in allergy & immunology2016
Cutaneous Manifestations in Dermatomyositis: Key Clinical and Serological Features-a Comprehensive Review.
Review in Clinical reviews in allergy & immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 1 synthesis or guideline pooled it, 153 citations in OpenAlex.
- Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis.Oncotarget · 2017Pooled it
- Site-level cutaneous phenotyping framework for anti-MDA5-positive dermatomyositis: exploratory associations with systemic immune reference markers.Arthritis research & therapy · 2026Article
- Idiopathic inflammatory myopathies: a comprehensive review, new concepts on diagnostic imaging and whole-body MRI.European radiology · 2026Review
- The Spectrum of Cutaneous Manifestations in Dermatomyositis: A Comprehensive Review.Journal of clinical medicine · 2026Review
- Paraneoplastic dermatomyositis with atypical features associated with a solid pseudopapillary pancreatic neoplasm.Clinical rheumatology · 2026Review
- Hyperglycemia-A Driver of Cutaneous Severity in Dermatomyositis: A Narrative Review.Journal of clinical medicine · 2026Review
- Case Report: breast cancer presenting as dermatomyositis.Frontiers in oncology · 2026Article
- Article
- The frequency of peripheral blood eosinophilia and its clinical significance in patients with dermatomyositis.GHM open · 2025Article
- [Cutaneous ulceration in dermatomyositis : Case reports with positive anti-NXP-2/anti-TIF1-gamma antibody status].Dermatologie (Heidelberg, Germany) · 2025Article
- A rare intersection: squamous cell carcinoma of the tonsil and the anti-TIF1 syndrome masquerade.BMC rheumatology · 2025Article
- Panniculitis in Anti-MDA-5 Positive Juvenile Dermatomyositis: A Case Report.JNMA; journal of the Nepal Medical Association · 2025Article
- Anti-MDA5 Antibody-positive Clinically Amyopathic Dermatomyositis with Rapidly Progressing Interstitial Lung Disease Successfully Treated by Initiation of Combined Immunosuppressive Therapy Plus Plasma Exchange and Subsequently Switching Tacrolimus to Tofacitinib.Internal medicine (Tokyo, Japan) · 2024Article
- Refractory antimelanoma differentiation-associated gene 5 antibody negative ulcerative dermatomyositis responsive to mycophenolate mofetil.JAAD case reports · 2024Article
- Anti-nuclear matrix protein 2 antibody-positive amyopathic dermatomyositis presenting in a patient with prostate cancer: A case report.Clinical case reports · 2024Article
- Anti-TIF1γ-Dermatomyositis and Sjögren's Syndrome As the Inaugural Presentation for Rectal Cancer.Cureus · 2024Article
- Amyopathic dermatomyositis may be on the spectrum of autoinflammatory disease: A clinical review.Rheumatology and immunology research · 2024Review
- Clinical features of macrophage activation syndrome in adult dermatomyositis: A single-center retrospective case-control study.Immunity, inflammation and disease · 2024Article
- Dermatomyositis: Practical Guidance and Unmet Needs.ImmunoTargets and therapy · 2024Review
- Dermatomyositis with Eosinophils.Dermatopathology (Basel, Switzerland) · 2023Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dermatomyositis (DM) is a common idiopathic inflammatory myopathy. The pathogenesis is considered to be microangiopathy affecting skin and muscle. The cutaneous manifestations of DM are the most important aspect of this disease, and their correct evaluation is important for early diagnosis. The skin signs are various: Some are pathognomonic or highly characteristic, and others are compatible with DM. Recently, DM has been categorized into several disease subsets based on the various autoantibodies present in patients. Sometimes, characteristic cutaneous manifestations are strongly associated with the presence of specific autoantibodies. For example, anti-Mi-2 antibody is associated with the classic features of DM, including heliotrope rash, Gottron's papules, the V-neck sign, the shawl sign, cuticular overgrowth, and photosensitivity. Frequent cutaneous features in anti-transcriptional intermediary factor 1 gamma (TIF1γ)-positive patients are diffuse photoerythema, including "dusky red face," while skin ulcerations, palmar papules (inverse Gottron), diffuse hair loss, panniculitis, and oral pain and/or ulcers are sometimes associated with anti-melanoma differentiation-associated gene 5 product (MDA5) antibody. Here, we review important cutaneous manifestations seen in patients with DM, and we examine the relationship between the skin changes and myositis-associated autoantibodies. Correct evaluation of cutaneous manifestations and myositis-associated autoantibodies should help the clinician in the early diagnosis of DM, for a quick recognition of cutaneous signs that may be the symptom of onset before muscle inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.